

BTLA Protein, Human, Recombinant (isoform2, His)

General Information

Synonyms:	CD272;BTLA1
Protein Construction:	A DNA sequence encoding the Human BTLA (NP_001078826.1) (Met1-Thr134) was expressed with a polyhistidine tag at the C-terminus.
Species:	Human
Expression Host:	HEK293 Cells
Accession:	Q7Z6A9-2
Molecular Weight:	13.47 kDa (predicted); 30 kDa (reducing condition)

QC Testing

Biological Activity:	Immobilized BTLA Protein, Human, Recombinant (aa 1-134, His) (Cat#TMPY-07085) at 2 µg/ml (100 µl/well) can bind Recombinant Mouse HVEM/TNFRSF14 Protein (His & Fc Tag), the EC50 is 11-33 ng/mL.
Purity:	≥ 95% as determined by SDS-PAGE. ≥ 95% as determined by SEC-HPLC.
Endotoxin:	< 1.0 EU/µg of the protein as determined by the LAL method.
Formulation:	Lyophilized from sterile PBS, pH 7.4. Please contact us for any concerns or special requirements. Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Preparation and Storage

Reconstitution:
Please refer to the lot-specific COA.

Stability & Storage:

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

Shipping:

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

Protein Background

BTLA is an inhibitory molecule which belongs to the Ig superfamily. It down-modulates immune responses. As such, reagents that regulate the binding of BTLA to its ligand or alter BTLA signaling have significant therapeutic promise. BTLA is crucial to understand the mechanism(s) of action of these antibodies before attempting clinical

applications. BTLA is not expressed by naive T cells, but it is induced during activation and remains expressed on T helper type 1 (T(H)1) but not T(H)2 cells. BTLA is a third inhibitory receptor on T lymphocytes with similarities to cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1). Cancer Immunotherapy Co-inhibitory Immune Checkpoint Targets Immune Checkpoint Targets Immunotherapy Targeted Therapy

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481